FDA Inspection
EyePoint Pharmaceuticals, Inc.EyePoint Pharmaceuticals, Inc. – FDA Inspection, Feb 15, 2024
Record Details
This FDA Inspection record concerns EyePoint Pharmaceuticals, Inc., with an inspection on February 15, 2024, issued by the New England District Office, covering human drugs.
View Company Profile
ID · 96011f71-7dc7-4d1e-af2a-8fb571d5f403
Inspection Facts
- Inspection number
- 1230113
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
7- 21 CFR 211.100(b)Procedure Deviations Recorded and Justified
- 21 CFR 211.110(a)Control procedures to monitor and validate performance
- 21 CFR 211.113(b)Procedures for sterile drug products
- 21 CFR 211.186(a)Master production and control records, procedure
- 21 CFR 211.192Investigations of discrepancies, failures
- 21 CFR 211.42(c)(10)(v)Cleaning System
- 21 CFR 211.67(a)Cleaning / Sanitizing / Maintenance
Full citation text and observation details available on the Dashboard.
Other FDA inspections of EyePoint Pharmaceuticals, Inc.
4| Date | Classification | Office | Project area |
|---|---|---|---|
| September 1, 2021 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 28, 2019 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 19, 2018 | Not classified | New England District Office | |
| April 4, 2018 | OAI | New England District Office | New Drug Evaluation |
Other documents for EyePoint Pharmaceuticals, Inc.
- FDA Inspection 1150669 - 2021-09-01
- FDA Inspection 1102130 - 2019-08-28
- FDA Inspection 1067552 - 2018-09-19
- FDA Inspection 1046783 - 2018-04-04
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.